Cargando…

Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m.

AIMS: Ivabradine has been approved in heart failure with reduced ejection fraction (HFrEF) and elevated heart rate despite guideline‐directed medical therapy (GDMT) to reduce cardiovascular (CV) death and hospitalization for worsening HF. The median value of 77 b.p.m. is the lower bound selected for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bouabdallaoui, Nadia, O'Meara, Eileen, Bernier, Virginie, Komajda, Michel, Swedberg, Karl, Tavazzi, Luigi, Borer, Jeffrey S., Bohm, Michael, Ford, Ian, Tardif, Jean‐Claude
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6989297/ https://www.ncbi.nlm.nih.gov/pubmed/31591826 http://dx.doi.org/10.1002/ehf2.12513

Ejemplares similares

Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy
por: Tardif, Jean-Claude, et al.
Publicado: (2011)

Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study
por: Borer, Jeffrey S., et al.
Publicado: (2012)

Effect of Visit‐to‐Visit Variation of Heart Rate and Systolic Blood Pressure on Outcomes in Chronic Systolic Heart Failure: Results From the Systolic Heart Failure Treatment With the I (f) Inhibitor Ivabradine Trial (SHIFT) Trial
por: Böhm, Michael, et al.
Publicado: (2016)

Efficacy of ivabradine in heart failure patients with a high‐risk profile (analysis from the SHIFT trial)
por: Abdin, Amr, et al.
Publicado: (2023)

Budget Impact of Adding Ivabradine to Standard of Care in Patients with Chronic Systolic Heart Failure in the United States
por: Borer, Jeffrey S., et al.
Publicado: (2016)

Role of Ivabradine in Patients with Heart Failure with Preserved Ejection Fraction
por: Nadeem, Muhammad, et al.
Publicado: (2020)

Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction
por: Lee, Ying‐Hsiang, et al.
Publicado: (2021)

Effect of ivabradine on ventricular arrhythmias in heart failure patients with reduced ejection fraction
por: Pay, Levent, et al.
Publicado: (2023)

Patient factors associated with titration of medical therapy in patients with heart failure with reduced ejection fraction: data from the QUALIFY international registry
por: Cowie, Martin R., et al.
Publicado: (2021)

Ivabradine in heart failure patients with reduced ejection fraction and history of paroxysmal atrial fibrillation
por: Lin, Yu‐Sheng, et al.
Publicado: (2022)

Ivabradine tolerability in heart failure
por: Birkhoelzer, Sarah, et al.
Publicado: (2018)

The role of Ivabradine in Diastolic Heart Failure with preserved Ejection Fraction. A Doppler-Echocardiographic study
por: Cacciapuoti, Federico, et al.
Publicado: (2017)

Cost-Effectiveness Analysis of the Adjunctive Therapy of Ivabradine for the Treatment of Heart Failure with Reduced Ejection Fraction
por: Krittayaphong, Rungroj, et al.
Publicado: (2019)

Advances in the management of heart failure: the role of ivabradine
por: Müller-Werdan, Ursula, et al.
Publicado: (2016)

Heart Rate Reduction by Ivabradine: Slowly but Surely?
por: Kojonazarov, Baktybek
Publicado: (2020)

Effect of ivabradine on hospitalization of heart failure patients with reduced left ventricular ejection fraction: A retrospective cohort study
por: Al-Balushi, Sara, et al.
Publicado: (2020)

Impact of ivabradine on the cardiac function of chronic heart failure reduced ejection fraction: Meta‐analysis of randomized controlled trials
por: Bryan Richard, Sasmita, et al.
Publicado: (2021)

Successful treatment with ivabradine in a β‐blocker‐refractory patient with acute decompensated heart failure with reduced ejection fraction
por: Inoue, Tomoko, et al.
Publicado: (2023)

Ivabradine in Cardiovascular Disease: Heart Rate Isn't Everything
por: Feldman, Arthur M.
Publicado: (2015)

Impact of Ivabradine on Inflammatory Markers in Chronic Heart Failure
por: Rohm, Ilonka, et al.
Publicado: (2016)

Ivabradine: An Intelligent Drug for the Treatment of Ischemic Heart Disease
por: Riccioni, Graziano
Publicado: (2012)

Cost‐Effectiveness of Ivabradine for Heart Failure in the United States
por: Kansal, Anuraag R., et al.
Publicado: (2016)

Ivabradine in Congestive Heart Failure: Patient Selection and Perspectives
por: Sattar, Yasar, et al.
Publicado: (2019)

Ivabradine Ameliorates Cardiac Function in Heart Failure with Preserved and Reduced Ejection Fraction via Upregulation of miR-133a
por: Shao, Shuai, et al.
Publicado: (2021)

Predictors and Outcomes of Heart Failure With Preserved Ejection Fraction in Patients With a Left Ventricular Ejection Fraction Above or Below 60%
por: Nakagawa, Akito, et al.
Publicado: (2022)

Adjuvant Use of Ivabradine in Acute Heart Failure due to Myocarditis
por: Franke, Jennifer, et al.
Publicado: (2011)

Combined effects of ivabradine with dobutamine or levosimendan in isolated perfused hearts
por: Konrad, D, et al.
Publicado: (2013)

Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece
por: Kourlaba, Georgia, et al.
Publicado: (2014)

Risk-benefit assessment of ivabradine in the treatment of chronic heart failure
por: Urbanek, Irmina, et al.
Publicado: (2014)

Ivabradine for junctional ectopic tachycardia in post congenital heart surgery
por: Kumar, Vivek, et al.
Publicado: (2017)

Heart rate manipulation in dilated cardiomyopathy: Assessing the role of Ivabradine
por: Raja, Deep Chandh, et al.
Publicado: (2018)

Association of ivabradin use with ventricular arrhythmias in heart failure patients
por: Pay, L, et al.
Publicado: (2023)

Ivabradine in patients with heart failure: a systematic literature review
por: Khan, Zeba M., et al.
Publicado: (2023)

Ivabradine: the evidence of its therapeutic impact in angina
por: Marquis-Gravel, Guillaume, et al.
Publicado: (2008)

Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction
por: Shen, Li, et al.
Publicado: (2019)

Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction
por: Shen, Li, et al.
Publicado: (2020)

Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency(†)
por: Ponikowski, Piotr, et al.
Publicado: (2015)

Using complexity metrics with R-R intervals and BPM heart rate measures
por: Wallot, Sebastian, et al.
Publicado: (2013)

Right ventricular function and its coupling to pulmonary circulation predicts exercise tolerance in systolic heart failure
por: Legris, Valéry, et al.
Publicado: (2021)

Ivabradine, the pure heart rate-lowering drug, shown to reduce morbidity and mortality in heart failure
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_tjb2fnj488ashp3hnqrgg6apfa